REFERENCES
- Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 2002; 25: 173–197, [INFOTRIEVE], [CSA]
- Imperato A K, Smiles S, Abramson S B. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol 2004; 16: 199–205, [INFOTRIEVE], [CROSSREF], [CSA]
- Kekow J, Welte T, Kellner U, Pap T. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept. Arthritis Rheum 2002; 46: 843–844, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shakoor N, Michalska M, Harris C A, Block J A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579–580, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kaipiainen-Seppanen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2003; 62: 88–89, [INFOTRIEVE], [CROSSREF], [CSA]
- Reddy A R, Backhouse O C. Does etanercept induce uveitis?. Br J Ophthalmo 2003; 87: 925, [CROSSREF], [CSA]
- Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001; 44: 1411–1415, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hashkes P J, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 2003; 21: 645–646, [INFOTRIEVE], [CSA]
- Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093–1101, [INFOTRIEVE], [CROSSREF], [CSA]
- Horneff G, Schmeling H, Biedermann T, et al. The German Etanercept Registry for treatment of juvenile idiopathic arthritis (JIA). Ann Rheum Dis 2004; 63: 1638–1644, [INFOTRIEVE], [CROSSREF], [CSA]
- Smith J R, Levinson R D, Holland G N, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001; 45: 252–257, [INFOTRIEVE], [CROSSREF], [CSA]
- Tiliakos A N, Tiliakos N A. Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary?. J Rheumatol 2003; 30: 2727, [INFOTRIEVE], [CSA]
- Caramaschi P, Biasi D, Carletto A, Bambara L M. Orbital myositis in a rheumatoid arthritis patient during etanercept treatment. Clin Exp Rheumatol 2003; 21: 136–137, [INFOTRIEVE], [CSA]
- Miller F W, Hess E V, Clauw D J, et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000; 43: 243–249, [INFOTRIEVE], [CROSSREF], [CSA]
- Mohan N, Edwards E T, Cupps T R, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862–2869, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- De Vos A F, Van Haren M A, Verhagen C, Hoekzema R, Kijlstra A. Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. Exp Eye Res 1995; 61: 667–675, [INFOTRIEVE], [CROSSREF], [CSA]
- Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci 1994; 35: 3884–3889, [INFOTRIEVE], [CSA]
- Smith J R, Hart P H, Coster D J, Williams K A. Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1998; 39: 658–661, [INFOTRIEVE], [CSA]
- Kasner L, Chan C C, Whitcup S M, Gery I. The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1993; 34: 2911–2917, [INFOTRIEVE], [CSA]
- Mo J S, Matsukawa A, Ohkawara S, Yoshinaga M. Involvement of TNF alpha, IL-1 beta and IL-1 receptor antagonist in LPS-induced rabbit uveitis. Exp Eye Res 1998; 66: 547–557, [INFOTRIEVE], [CROSSREF], [CSA]
- Dick A D, Duncan L, Hale G, Waldmann H, Isaacs J. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun 1998; 11: 255–264, [INFOTRIEVE], [CROSSREF], [CSA]
- Rosenbaum J T. Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis Rheum 2004; 50: 3736–3737, [INFOTRIEVE], [CROSSREF], [CSA]